

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	11/12/2003

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
ICN Pharmaceuticals, Inc.		11/10/2003	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

Name:	Valeant Pharmaceuticals International
Street Address:	3300 Hyland Ave.
Internal Address:	Legal Dept.
City:	Costa Mesa
State/Country:	CALIFORNIA
Postal Code:	92626
Entity Type:	CORPORATION: DELAWARE

**PROPERTY NUMBERS Total: 29**

Property Type	Number	Word Mark
Serial Number:	78206780	C+
Serial Number:	78121007	GLYQUIN XM
Serial Number:	78105715	VITAL ELEMENTS
Serial Number:	78105712	NUTRI-A
Serial Number:	78105710	DAILY ZINC
Serial Number:	78094595	ANCOBON
Serial Number:	78094073	LIBRIUM
Serial Number:	78093291	EFUDEX
Serial Number:	76064998	VIRAMIDINE
Serial Number:	76064924	ADENAZOLE
Serial Number:	75812950	GLYQUIN
Serial Number:	75156621	ACCUPEEL

OP \$740.00 78206780

Serial Number:	75035429	INSTA-GLUCOSE
Serial Number:	74161669	HOLD MY HAND
Serial Number:	74150924	GLY DERM
Serial Number:	73799841	OXSORALEN-ULTRA
Serial Number:	73776084	SPAG
Serial Number:	73593882	ANDROID
Serial Number:	73560695	ICN
Serial Number:	73372864	TESTRED
Serial Number:	73233285	FOTOTAR
Serial Number:	73128107	ELDOPAQUE
Serial Number:	73128079	VITADYE
Serial Number:	73127178	ELDOPAQUE-FORTE
Serial Number:	73053886	BENOQUIN
Serial Number:	72113999	LIBRAX
Serial Number:	71655783	MESTINON
Serial Number:	71611572	TENSILON
Serial Number:	71322016	PROSTIGMIN

**CORRESPONDENCE DATA**

Fax Number: (714)641-7274  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 714-545-0100  
Email: mhmarshall@valeant.com  
Correspondent Name: Matthew Marshall  
Address Line 1: 3300 Hyland Ave.  
Address Line 2: Legal Dept.  
Address Line 4: Costa Mesa, CALIFORNIA 92626

ATTORNEY DOCKET NUMBER:	ICN ASSIGN
NAME OF SUBMITTER:	Matthew Marshall
Signature:	/matthew marshall/
Date:	03/14/2006

Total Attachments: 6  
source=CertOfInc#page1.tif  
source=CertOfInc#page2.tif  
source=CertOfInc#page3.tif  
source=CertOfInc#page4.tif  
source=CertOfInc#page5.tif



# Delaware

PAGE 1


*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"ICN MERGER SUBSIDIARY, INC.", A DELAWARE CORPORATION, WITH AND INTO "ICN PHARMACEUTICALS, INC." UNDER THE NAME OF "VALEANT PHARMACEUTICALS INTERNATIONAL", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TENTH DAY OF NOVEMBER, A.D. 2003, AT 8:17 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF OWNERSHIP IS THE TWELFTH DAY OF NOVEMBER, A.D. 2003, AT 12:01 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE AND KENT COUNTY RECORDER OF DEEDS.



*Harriet Smith Windsor*

Harriet Smith Windsor, Secretary of State

2422691 8100M

030721781

AUTHENTICATION: 2741182

DATE: 11-12-03

TRADEMARK  
REEL: 003268 FRAME: 0396

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

ICN MERGER SUBSIDIARY, INC.

WITH AND INTO

ICN PHARMACEUTICALS, INC.

Pursuant to Section 253 of the General Corporation Law of the State of Delaware, ICN Pharmaceuticals, Inc., a Delaware corporation (the "Company"), does hereby certify to the following facts relating to the merger (the "Merger") of ICN Merger Subsidiary, Inc., a Delaware corporation (the "Subsidiary"), with and into the Company, with the Company remaining as the surviving corporation:

**FIRST:** The Company is incorporated pursuant to the General Corporation Law of the State of Delaware (the "DGCL"). The Subsidiary is incorporated pursuant to the DGCL.

**SECOND:** The Company owns all of the outstanding shares of each class of capital stock of the Subsidiary.

**THIRD:** The Board of Directors of the Company, by the following resolutions duly adopted on October 29, 2003, determined to merge the Subsidiary with and into the Company pursuant to Section 253 of the DGCL:

*Resolutions of  
Board of Directors  
of ICN Pharmaceuticals, Inc.*

*WHEREAS, ICN Pharmaceuticals, Inc. a Delaware corporation (the "Company"), owns all of the outstanding shares of the capital stock of ICN Merger Subsidiary, Inc., a Delaware corporation (the "Subsidiary"); and*

*WHEREAS, the Board of Directors of the Company has deemed it advisable that the Subsidiary be merged with and into the Company pursuant to Section 253 of the General Corporation Law of the State of Delaware;*

*NOW, THEREFORE, BE IT RESOLVED, that, effective upon the filing of (or at such subsequent time as may be specified in) the Certificate of Ownership and Merger filed in respect thereof (the "Effective Time"), the Subsidiary shall be merged with and into the Company with the Company being the surviving corporation (the "Merger");*

*FURTHER RESOLVED, that it is intended that the Merger qualify as a tax-free reorganization under Section 368(a)(1)(F) of the Internal Revenue Code of 1986, as amended, and that these resolutions constitute a plan of reorganization within the meaning of Section 368;*

*FURTHER RESOLVED, that, at any time prior to the Effective Time, the Merger may be amended, modified, terminated or abandoned by action of the Board of Directors of the Company;*

*FURTHER RESOLVED, that by virtue of the Merger and without any action on the part of the holder thereof, each then outstanding share or treasury share of capital stock of the Company shall remain unchanged and continue to remain outstanding or held in treasury, respectively, as one share of capital stock of the Company, held by the person who was the holder of such share of capital stock of the Company immediately prior to the Merger;*

*FURTHER RESOLVED, that by virtue of the Merger and without any action on the part of the holder thereof, each then outstanding share of common stock of the Subsidiary shall be cancelled and no consideration shall be issued in respect thereof;*

*FURTHER RESOLVED, that the Restated Certificate of Incorporation of the Company as in effect immediately prior to the effective time of the Merger shall be the certificate of incorporation of the surviving corporation, except that Article I thereof shall be amended to read in its entirety as follows:*

**"ARTICLE I**

*The name of the corporation is "Valeant Pharmaceuticals International."*

*FURTHER RESOLVED, that, effective immediately following the Effective Time, the Bylaws of the Company shall be amended by deleting the name "ICN Pharmaceuticals, Inc." from the heading thereof and substituting therefor the name "Valeant Pharmaceuticals International";*

*FURTHER RESOLVED, that each officer of the Company is authorized to make and execute a Certificate of Ownership and Merger setting forth a copy of these resolutions, and the date of adoption thereof, in the discretion of such officer to specify therein an Effective Time subsequent to the filing thereof and to file the same in the office of the Secretary of State of the State of Delaware;*

*FURTHER RESOLVED, that in connection with changing the Company's name, each officer of the Company is authorized, in the name and on behalf of the Company, to enter into any agreements with the office of the Secretary of State of the State of Delaware, and to make and execute such additional certificates and to file the same in the office of the Secretary of State of the State of Delaware, in each case as may, in his or her judgment, be required or advisable;*

*FURTHER RESOLVED, that in order for the Company to comply with all applicable regulations and requirements of federal, state, local and foreign governmental agencies and exchanges, each officer of the Company is authorized, in the name and on behalf of the Company, to prepare, execute and file or cause to be filed all reports, statements, documents, undertakings, commitments and*

information with any exchange or governmental agencies as may, in his or her judgment, be required or advisable in connection with the Merger or the Company's name change;

*FURTHER RESOLVED*, that, after the Effective Time, each officer of the Company is hereby authorized, in the name and on behalf of the Company, to apply to, and to take such steps and to execute such documents as may be necessary or desirable to, change the name in which the Company is qualified to do business, in such jurisdictions as it is qualified, to reflect the change in the Company's name;

*FURTHER RESOLVED*, that, after the Effective Time, each officer of the Company is hereby authorized, in the name and on behalf of the Company, to apply to, and to take such steps and to execute such documents as may be necessary or desirable to, use any alternate name, fictitious name, assumed name or other name in such jurisdictions as the Company is qualified, if such officer determines it is necessary or desirable for the Company to use an alternate name, fictitious name, assumed name or other name;

*FURTHER RESOLVED*, that, after the Effective Time, each officer of the Company is hereby authorized, in the name and on behalf of the Company, to prepare, execute and file a listing application or supplemental listing application, and such other documents, and to take such steps, as may be necessary or desirable, with the New York Stock Exchange and, if such officer determines it required or advisable, any other exchanges on which the Company has listed securities, to reflect the change in the Company's name;

*FURTHER RESOLVED*, that all actions to be taken or heretofore taken by any officer or agent of the Company in connection with any matter referred to or contemplated by any of the foregoing resolutions be, and they hereby are, approved, ratified and confirmed in all respects;

*FURTHER RESOLVED*, the form of certificate for the common stock of the Company attached hereto as Exhibit A is hereby approved and adopted;

*FURTHER RESOLVED*, that the corporate seal for the Company in the form impressed on Exhibit B hereto is hereby approved and adopted; and

*FURTHER RESOLVED*, that each officer of the Company is authorized to do all acts and things and to sign, seal, execute, acknowledge, file, deliver and record all papers, instruments, agreements, documents and certificates, and to pay all charges, fees, taxes and other expenses, from time to time necessary, desirable or appropriate to be done, signed, sealed, executed, acknowledged, filed, delivered, recorded or paid, under any applicable law, or otherwise, and to certify as having been adopted by this Board of Directors any form of resolution required by any law, regulation or agency, in order to effectuate the purpose of

*the foregoing resolutions or any of them or to carry out the transactions contemplated hereby.*

FOURTH: The Company shall be the surviving corporation of the Merger. The name of the surviving corporation shall be amended in the Merger to be "Valeant Pharmaceuticals International."

FIFTH: The Restated Certificate of Incorporation of the Company as in effect immediately prior to the effective time of the Merger shall be the certificate of incorporation of the surviving corporation, except that Article I thereof shall be amended to read in its entirety as follows:

"ARTICLE I

The name of the corporation is "Valeant Pharmaceuticals International"

SIXTH: This Certificate of Ownership and Merger, and the Merger provided for herein, and shall become effective at 12:01 a.m., Eastern Standard Time, on November 12, 2003.

IN WITNESS WHEREOF, the Company has caused this Certificate of Ownership and Merger to be executed by its duly authorized officer this 10th day of November, 2003.

ICN PHARMACEUTICALS, INC.

By: 

Name: Gary G. Bailey

Title: Executive Vice President and Chief Financial Officer




OFFICER'S CERTIFICATE

In support of a request by ICN Pharmaceuticals, Inc. (the "Company") for a waiver of the name requirements of Section 102(1)(i) of the Delaware General Corporation Law, in connection with the Company's Certificate of Ownership and Merger dated as of November 12, 2003, the undersigned hereby certifies to the Delaware Secretary of State as of the date set forth below and as of the effective date of the Certificate of Ownership and Merger that:

1. He is the duly elected, qualified and acting Executive Vice President and Chief Financial Officer of the Company.

2. The total assets of the Company, as defined in Section 503 of the Delaware General Corporation Law, are no less than \$10,000,000.

Dated November 10, 2003.

  
Barry G. Bailey  
Executive Vice President and  
Chief Financial Officer

W02-LA-1028100639031.1